Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to buy Icagen for $56m

Pfizer has entered a definitive agreement to purchase pain research specialists Icagen for $56m

Pfizer has entered a definitive agreement to purchase pain research specialists Icagen for $56m.

Pfizer currently owns around 11 per cent of the biotechnology company, and will acquire the remaining 8.3 million shares for $6.00 per share.

In June 2011, it was reported that Pfizer was considering a "strategic transaction" with Icagen.

The companies have previously worked together as part of a partnership to develop and commercialise compounds as new potential treatments for pain and related disorders.

Following the takeover, Pfizer and Icagen will continue to target three sodium ion channels that play a role in the generation of electrical signals in nerve fibres related to pain.

"During the nearly four years since the initiation of our collaboration, each side has developed a mutual appreciation of the expertise and capabilities of the other," said Dr P Kay Wagoner, CEO, Icagen. "By joining forces in a more integrated manner, we believe that our joint efforts towards the identification and development of novel pharmaceuticals targeting specific ion channels will be significantly enhanced."

21st July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics